Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 4/20 | 0.36 |
| ▸ | PNLIP | P16233 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589038 | 1.00 | GLS (0.37) | GLSPRKCAPNLIPEPHX2KEAP1 | |
| SCHEMBL13345378 | 0.83 | GLS (0.38) | GLSPRKCAKEAP1NFE2L2HCAR2 | |
| SCHEMBL3587679 | 0.75 | TSHR (0.40) | GLSEPHX2MAPT | |
| SCHEMBL31681514 | 0.71 | HCAR2 (0.55) | PRKCAEPHX2KEAP1NFE2L2HCAR2 | |
| SCHEMBL23533375 | 0.71 | KEAP1 (0.35) | PRKCAKEAP1NFE2L2HCAR2MAPT | |
| SCHEMBL11191261 | 0.70 | PPARG (0.42) | GLS | |
| SCHEMBL10774158 | 0.69 | HCAR2 (0.48) | PRKCAKEAP1NFE2L2HCAR2MAPT | |
| SCHEMBL18916559 | 0.69 | GLS (0.47) | GLSMAPT | |
| SCHEMBL1623010 | 0.69 | GLS (0.47) | GLSMAPT | |
| SCHEMBL16287745 | 0.69 | HCAR2 (0.40) | PRKCAKEAP1NFE2L2HCAR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
| EP-2137169-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110583-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110583-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | HDAC3, HCCS, CCNH | GLS 431/4885PRKCA 3624/4885PNLIP 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.